Systematic measurement of combination-drug landscapes to predict in vivo treatment outcomes for tuberculosis
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
A lengthy multidrug chemotherapy is required to achieve a durable cure in tuberculosis. Variation in Mycobacterium tuberculosis drug response is created by the differing microenvironments in lesions, which generate different bacterial drug susceptibilities. To better realize the potential of combination therapy to shorten treatment duration, multidrug therapy design should deliberately explore the vast combination space. We face a significant scaling challenge in making systematic drug combination measurements because it is not practical to use animal models for comprehensive drug combination studies, nor are there well-validated high-throughput in vitro models that predict animal outcomes. We hypothesized that we could both prioritize combination therapies and quantify the predictive power of various in vitro models for drug development using a dataset of drug combination dose responses measured in multiple in vitro models. We systematically measured M. tuberculosis response to all 2- and 3-drug combinations among ten antibiotics in eight conditions that reproduce lesion microenvironments. Applying machine learning to this comprehensive dataset, we developed classifiers predictive of multidrug treatment outcome in a mouse model of disease relapse. We trained classifiers on multiple mouse models and identified ensembles of in vitro models that best describe in vivo treatment outcomes. Furthermore, we found that combination synergies are less important for predicting outcome than metrics of potency. Here, we map a path forward to rationally prioritize combinations for animal and clinical studies using systematic drug combination measurements with validated in vitro models. Our pipeline is generalizable to other difficult-to-treat diseases requiring combination therapies. One Sentence Summary Signatures of in vitro potency and drug interaction measurements predict combination therapy outcomes in mouse models of tuberculosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wickham, H., Averick, M., Bryan, J., Chang, W., McGowan, L., François, R., Grolemund, G., Hayes, A., Henry, L., Hester, J., et al. (2019) · Journal of Open Source Software · doi:10.21105/joss.01686 · Cited by 22,138
Ishwaran, H., Kogalur, U. B., Blackstone, E. H., & Lauer, M. S. (2008) · The Annals of Applied Statistics · doi:10.1214/08-aoas169 · Cited by 2,714
Betts, J. C., Lukey, P. T., Robb, L. C., McAdam, R. A., & Duncan, K. (2002) · Molecular Microbiology · doi:10.1046/j.1365-2958.2002.02779.x · Cited by 1,395
Pai, M., Behr, M. A., Dowdy, D., Dheda, K., Divangahi, M., Boehme, C. C., Ginsberg, A., Swaminathan, S., Spigelman, M., Getahun, H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.76 · Cited by 1,270
Analysis of drug combinations: current methodological landscape
Foucquier, J., & Guedj, M. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.149 · Cited by 1,115
Mycobacterial persistence requires the utilization of host cholesterol
Pandey, A. K., & Sassetti, C. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711159105 · Cited by 1,064 · cited 2×
“This is consistent with the importance of cholesterol metabolism for Mtb survival and infectivity (24, 85-87).”
Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs
Hafner, M., Niepel, M., Chung, M., & Sorger, P. K. (2016) · Nature Methods · doi:10.1038/nmeth.3853 · Cited by 681
Palmer, A. C., & Sorger, P. K. (2017) · Cell · doi:10.1016/j.cell.2017.11.009 · Cited by 642
Rock, J. M., Hopkins, F. F., Chavez, A., Diallo, M., Chase, M. R., Gerrick, E. R., Pritchard, J. R., Church, G. M., Rubin, E. J., Sassetti, C. M., et al. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.274 · Cited by 538
Intracellular Mycobacterium tuberculosis Exploits Host-derived Fatty Acids to Limit Metabolic Stress
Lee, W., VanderVen, B. C., Fahey, R. J., & Russell, D. G. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.445056 · Cited by 424
Quantifying drug combination synergy along potency and efficacy axes
Meyer, C. T., Wooten, D. J., Paudel, B. B., Bauer, J., Hardeman, K. N., Westover, D., Lovly, C. M., Harris, L. A., Tyson, D. R., & Quaranta, V. (2019) · Cell Systems · doi:10.1016/j.cels.2019.01.003 · Cited by 202
Leveraging Uncertainty in Machine Learning Accelerates Biological Discovery and Design
Hie, B., Bryson, B. D., & Berger, B. (2020) · Cell Systems · doi:10.1016/j.cels.2020.09.007 · Cited by 154 · cited 1×
“We expect this pipeline to improve as the component drug set is expanded and diversified via new drug discovery methods (Hie et al., 2020; Johnson et al., 2019; Rock, 2019; Rock et al., 2017; VanderVen et al., 2015; Bryk et al., 2008; Gold and Nathan, 2017; Gold et al., 2015) and as more animal studies provide outcome…”
Differential Antibiotic Susceptibilities of Starved Mycobacterium tuberculosis Isolates
Xie, Z., Siddiqi, N., & Rubin, E. J. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4778-4780.2005 · Cited by 136 · cited 1×
“Isoniazid potency was lower in the dormancy model, consistent with its inactivity toward nonreplicating bacilli (Xie et al., 2005; Betts et al., 2002; Wayne and Sramek, 1994) and previous studies showing decreased efficacy in the presence of nitrite (Cunningham-Bussel et al.”
ResultShim, D., Kim, H., & Shin, S. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00910 · Cited by 113
Nitrate Enhances the Survival of Mycobacterium tuberculosis during Inhibition of Respiration
Sohaskey, C. D. (2008) · Journal of Bacteriology · doi:10.1128/jb.01857-07 · Cited by 108
Puckett, S., Trujillo, C., Eoh, H., Marrero, J., Spencer, J., Jackson, M., Schnappinger, D., Rhee, K., & Ehrt, S. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004144 · Cited by 72 · cited 1×
“our in vitro models because of the important role of lipids and cholesterol specifically for Mtb growth, survival, and infectivity (81-90).”
Background
Cited by
Anti-tuberculosis treatment strategies and drug development: challenges and priorities
Dartois, V. A., & Rubin, E. J. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00731-y · Cited by 490
An RNA-Based Vaccine Platform for Use against Mycobacterium tuberculosis
Larsen, S. E., Erasmus, J. H., Reese, V. A., Pecor, T., Archer, J., Kandahar, A., Hsu, F.-C., Nicholes, K., Reed, S. G., Baldwin, S. L., et al. (2023) · Vaccines · doi:10.3390/vaccines11010130 · Cited by 66
Targeting de novo purine biosynthesis for tuberculosis treatment
Lamprecht, D. A., Wall, R. J., Leemans, A., Truebody, B., Sprangers, J., Fiogbe, P., Davies, C., Wetzel, J., Daems, S., Pearson, W., et al. (2025) · Nature · doi:10.1038/s41586-025-09177-7 · Cited by 24
Self-citation
Metadata
- Authors
- Larkins-Ford, J., Greenstein, T., Van, N., Degefu, Y. N., Olson, M. C., Sokolov, A., & Aldridge, B. B.
- Venue
- Cell Systems
- Publisher
- Elsevier BV
- Published
- 2021-11
- Volume
- 12
- Issue
- 11
- Pages
- 1046-1063.e7
- ISSN
- 2405-4712 (ISSN-L)
- OpenAlex
- W3197038756
- Cited by
- 72
- References
- 16
- FWCI
- 2.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.